ASH Clinical News May 2015 | Page 73

XYNTHA SOLOFUSE

Efficacy and reconstitution
convenience—together
XYNTHA SOLOFUSE is factor VIII with proven
efficacy and easy, all-in-one reconstitution
• XYNTHA® Antihemophilic Factor (Recombinant) successfully controlled
and prevented bleeds with 1 or 2 infusions administered prior to initiation
or during regular treatment1
– 92.5% of bleeds were treated successfully on demand with 1 or 2 infusions*
• The median annualized bleed rate for all bleeding episodes was 1.9 (3.9 mean)
and 45.7% of subjects had no bleeding episodes during regular treatment1
XYNTHA SOLOFUSE—Available in a wide range of doses1

250 IU

500 IU

1000 IU

2000 IU

3000 IU

Start your patients on XYNTHA SOLOFUSE…visit

www.FreeTrialPfizerFactor.com

• Across all studies, the most common adverse reactions
(≥10%) with XYNTHA in previously treated adult and pediatric
patients were headache (26% of subjects), arthralgia (25%),
fever (21%), and cough (11%). Other adverse reactions reported
in ≥5% of subjects were diarrhea, vomiting, weakness, and
nausea.
• XYNTHA is an injectable medicine administered by intravenous
(IV) infusion. Patients should be advised that local irritation
may occur when infusing XYNTHA after reconstitution in
XYNTHA® SOLOFUSE®.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
Please see brief summary of Full Prescribing
Information on next page.
RUS738508-01 © 2015 Pfizer Inc. All rights reserved.

REFERENCES: 1. XYNTHA® SOLOFUSE® Antihemophilic Factor
(Recombinant) [Prescribing Information]. Philadelphia, PA: Wyeth
Pharmaceuticals Inc; October 2014. 2. Recht M, Nemes L, Matysiak M,
et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation
of B-domain deleted recombinant factor VIII (BDDrFVIII) for
treatment of haemophilia A: demonstration of safety, efficacy, and
pharmacokinetic equivalence to full-length recombinant factor VIII.
Haemophilia. 2009;15(4):869-880.
*Results reported here for 53 patients (187 bleeding episodes) who
received 282 infusions of XYNTHA (median dose 30.6 IU/kg) over
6 months.1,2

Printed in USA/April 2015